As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a … Continue reading
Tag Archives: Leveraging
Pharma To Leverage The Art of Turning Challenges Into Opportunities, Now
Since, the dawn of the year 2020, the human population living in different countries, across the world are facing ‘lockdowns in different forms. Although essential, it severely restricts normal daily essential and other important activities of all. A large number … Continue reading
The Game is Changing: Ensure Better Treatment Outcomes: Leverage Technology
Today, several pharma players, mostly ‘encouraged’ by many non-pharma tech companies, are trying to gain, at least, a toehold in the digital health care space. It is visible even within the generic drug industry. Such initiatives, as they gain a … Continue reading
Focus On Patient Compliance To Boost Pharma Sales…And More…
One high-impact area in the healthcare space that often finds its place in the backseat is – patient noncompliance. A term that is commonly used in regard to ‘a patient who does not take a prescribed medication or follow a prescribed course … Continue reading
SCM: Embracing Technology For Patients’ Safety
Supply Chain Management (SCM) in the pharma industry is generally perceived as a logistic function, just in most other industries, involving the distribution of medicines from manufacturing plants, right up to pharma distributors. Thereafter, it becomes the responsibility of the … Continue reading
Leveraging Artificial Intelligence For Greater Patient-Centricity
‘Artificial Intelligence (AI)’ – the science of simulation of intelligent behavior in computers, has the potential to leave a transformational impact on virtually everything that we see and feel around us. As many will know, the modern definition of AI … Continue reading
Multi-channel Engagement: A New Normal In Pharma Marketing
The 2015 Report of AffinityMonitor reconfirms that access to important doctors for pharma Medical Representatives (MRs) continues to decline. Now, fewer than half of all doctors are truly accessible to the MRs, down from nearly 80 percent in 2008. In … Continue reading
Leveraging 3D Printing In Pharma, For Cost Containment And Patient-Centricity
Today, although a number of new and state of the art drugs is regularly being developed, and brought to the market at a reasonably rapid pace, their access to the majority of the global population has still remained a huge … Continue reading